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INTRODUCTION & OBJECTIVES: Biodegradable ureteral stents developed have proven to be an 
interesting alternative to conventional stents. Additionally, they could be applied as exceptional drug 
eluting stents, specially for urothelial tumours of upper urinary tract. In this case the conventional 
method of drug administration is via drug instillation. This has several drawbacks, such as high 
concentration dosage, increased side effects, short residence time and poor bioavailability. To avoid 
these problems, biodegradable ureteral stents impregnated by supercritical fluid CO2 (SCF) with four 
anti-cancer drugs were produced and their performance evaluated. 
   
MATERIAL & METHODS: The preparation of biodegradable stents was tested with four different 
formulations. The suitable concentration of gelatin and alginate and crosslinking agent was 
optimizedand bismuth  was added to confer radiopaque properties to the stent. The preliminary in 
vivo validation studies of the biodegradable stents was conducted in female domestic pigs at the 
University of Minho, Braga, after formal approval by the institution’s review board and in accordance 
with its internal ethical protocol for animal experiments. In which concerns drug eluting stents, 
paclitaxel, epirubicin, doxorubicin and gemcitabine were impregnated and the release kinetics in 
artificial urine solution (AUS) was followed for 9 days by UV spectroscopy in a microplate reader. The 
anti-tumoral effect of the developed stents in cancer cell line (T24) and HUVEC primary cells, used as 
control, was evaluated. 
RESULTS: The in vivo validation of this second-generation of ureteral stents performed was herein 
demonstrated. Biodegradable ureteral stents were placed in the ureters of a female pig, following 
the normal surgical procedure. The animals remained asymptomatic, with normal urine flow. The in 
vitro release study in AUS of the stents impregnated showed a higher release in the first 72h for the 
four anti-cancer drugs impregnated and after this time a plateau was achieved and the stent 
degraded after 9 days. The direct and indirect contact of the anti-cancer biodegradable stents with 
the T24 and HUVEC cell lines confirm the anti-tumour effect of the stents impregnated with the four 
anti-cancer drugs, reducing around 75% of the viability of the T24 cells after 72h and no killing effect 
in the HUVEC cells. 
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CONCLUSIONS: The use of biodegradable ureteral stents in urology clinical practice not only reduces 
the stent-related symptoms but also open new treatment therapy’s, like in urothelial tumours of 
upper urinary tract. We have herein demonstrated its clinical validation an in vivo model. And we 
have also shown the killing efficacy of the anti-cancer drug eluting biodegradable stents in vitro for 
the T24 cancer cells, with no toxicity observed in the control, non-cancer cells. 
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